Synonyms
Status
Molecule Category UNKNOWN
UNII 6GQP90I798
EPA CompTox DTXSID6046214

Structure

InChI Key SUPKOOSCJHTBAH-UHFFFAOYSA-N
Smiles Nc1ncnc2c1ncn2CCOCP(=O)(O)O
InChI
InChI=1S/C8H12N5O4P/c9-7-6-8(11-3-10-7)13(4-12-6)1-2-17-5-18(14,15)16/h3-4H,1-2,5H2,(H2,9,10,11)(H2,14,15,16)

Physicochemical Descriptors

Property Name Value
Molecular Formula C8H12N5O4P
Molecular Weight 273.19
AlogP -0.44
Hydrogen Bond Acceptor 7.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 5.0
Polar Surface Area 136.38
Molecular species ACID
Aromatic Rings 2.0
Heavy Atoms 18.0

Bioactivity

Mechanism of Action Action Reference
DNA polymerase/reverse transcriptase inhibitor INHIBITOR FDA
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Structural protein
83 - - - -
Assay Description Organism Bioactivity Reference
Inhibition of moloney sarcoma virus (MSV) induced cytopathicity in C3H/3T3 embryo fibroblast cells Moloney murine sarcoma virus 0.25 ug.mL-1
Compound was tested for antiviral activity against the CEM-SS cell lines infected with HIV-1. Homo sapiens 420.0 nM
Inhibition of Human immunodeficiency virus (HIV) -1 III B strain induced cytopathicity in CEM cell line None 1.8 ug.mL-1
Inhibition of Human immunodeficiency virus (HIV)-2 ROD strain induced cytopathicity in CEM cell line None 2.5 ug.mL-1
Cellular toxic effect was determined in CEM cells Homo sapiens 285.0 ug.mL-1
Inhibitory activity against herpes simplex virus type 1 (HSV-1) KOS strain Human herpesvirus 1 3.6 ug.mL-1
Inhibition of herpes simplex virus type 1 thymidine kinase (HSV-1 TK-) B2006 strain None 13.0 ug.mL-1
Inhibitory activity against herpes simplex virus type 1 (HSV-1) thymidine kinase (TK) VMW 1837 strain None 5.0 ug.mL-1
Inhibitory activity against herpes simplex virus type 2 (HSV-2) G strain Human herpesvirus 2 1.1 ug.mL-1
Inhibitory activity against vaccinia virus (VV) Vaccinia virus 1.14 ug.mL-1
Inhibition of Herpes simplex virus-1, KOS strain induced cytopathicity in E6SM cell line None 7.0 ug.mL-1
Inhibition of Herpes simplex virus-2 (G strain) induced cytopathicity in E6SM cell line None 7.0 ug.mL-1
Inhibition of thymidine kinase deficient Herpes simplex virus-1 VMW 1837 strain induced cytopathicity in E6SM cell line None 7.0 ug.mL-1
Concentration required to inhibit 50% of cytoplasmic HBV-DNA synthesis Human herpesvirus 1 200.0 nM
Inhibition of Thymidine kinase deficient (TK-) Varicella-Zoster virus (VZV) 07/1 strain induced cytopathicity n HEL cell line Human herpesvirus 3 10.0 ug.mL-1
Inhibition of Thymidine kinase deficient (TK-) Varicella-Zoster virus (VZV) YS/R strain induced cytopathicity in HEL cell line None 10.0 ug.mL-1
Inhibition of Varicella-Zoster virus (VZV) OKA strain induced cytopathicity in HEL cell line None 10.0 ug.mL-1
Inhibition of Varicella-Zoster virus (VZV) YS strain induced cytopathicity in HEL cell line None 10.0 ug.mL-1
Inhibition of cytopathogenicity against human HIV-1(IIIB) in MT-4 cells Human immunodeficiency virus 1 4.1 ug.mL-1
Inhibition of cytopathogenicity against human HIV-2(LAV-2) in MT-4 cells Human immunodeficiency virus 2 3.8 ug.mL-1
Inhibitory activity against cytomegalovirus (CMV) AD 169 strain Cytomegalovirus 30.0 ug.mL-1
Inhibitory activity against cytomegalovirus (CMV) Davis strain Cytomegalovirus 77.0 ug.mL-1
Inhibitory activity against varicella zoster virus thymidine kinase (VZV TK+) OKA strain Human herpesvirus 3 8.5 ug.mL-1
Inhibitory activity against varicella zoster virus thymidine kinase (VZV TK+) YS strain Human herpesvirus 3 5.4 ug.mL-1
Inhibition of varicella zoster virus thymidine kinase (VZV TK+) YS/R strain Human herpesvirus 3 18.0 ug.mL-1
Cellular toxic effect was determined in MT-4 cells Homo sapiens 274.0 ug.mL-1
Inhibition of antiviral activity against moloney murine sarcoma virus(MSV)in CEM cells in cell protection assay Moloney murine sarcoma virus 2.0 ug.mL-1
Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days Moloney murine leukemia virus 530.0 nM
Antiviral activity against ganciclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 5.8 ug.mL-1
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl cytosine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 18.0 ug.mL-1
Antiviral activity against (S)-3-hydroxy-2-phosphonomethoxypropyl adenine-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 9.1 ug.mL-1
Antiviral activity against foscarnet-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 128.0 ug.mL-1
Antiviral activity against acyclovir-resistant HCMV with DNA polymerase mutant in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 137.0 ug.mL-1
Antiviral activity against HCMV 6 with U97 mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 90.0 ug.mL-1
Antiviral activity against HCMV 521 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 20.0 ug.mL-1
Antiviral activity against HCMV 530 with U97 and DNA polymerase mutation in HEL cells assessed as reduction of virus-induced cytopathogenicity Human herpesvirus 5 42.0 ug.mL-1
Antiviral activity against Hepatitis B virus Hepatitis B virus 200.0 nM
Antiviral activity against Herpes simplex virus 1 Human herpesvirus 1 0.024 nM
Antiviral activity against Herpes simplex virus 2 Human herpesvirus 2 0.024 nM
Antiviral activity against HIV1 Human immunodeficiency virus 1 0.0033 nM
Antiviral activity against HIV2 Human immunodeficiency virus 2 0.0066 nM
Antiviral activity against Human cytomegalovirus Human herpesvirus 5 0.1 nM
Antiviral activity against Varicella zoster virus Human herpesvirus 3 0.035 nM
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of HBV DNA replication after 9 days by PCR Hepatitis B virus 517.0 nM
Antiviral activity against HIV1 clade D isolate 1649 infected in human H9 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 320.0 nM
Antiviral activity against HIV1 clade A/E isolate 2165 infected in human H9 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 320.0 nM
Antiviral activity against HIV1 clade F isolate 2338 infected in human H9 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 190.0 nM
Antiviral activity against HIV1 clade G isolate 3187 infected in human H9 cells assessed as inhibition of viral replication Human immunodeficiency virus 1 220.0 nM
Antiviral activity against HBV infected in human HepG2(2.2.15) cells assessed as inhibition of viral replication after 9 days by fluorescence PCR method Hepatitis B virus 517.0 nM
Inhibition of hepatitis B virus capsid assembly infected in human HepG2.215 cells assessed as reduction in viral DNA replication measured on day 7 by real time PCR analysis Hepatitis B virus 82.7 nM
Antiviral activity against HBV Hepatitis B virus 700.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 27.72 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 41.81 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 14.69 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.05 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.0 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.05 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.0 %

Related Entries

Cross References

Resources Reference
ChEBI 2469
ChEMBL CHEMBL484
DrugBank DB13868
FDA SRS 6GQP90I798
KEGG C11277
PDB 5HG
PubChem 60172
SureChEMBL SCHEMBL49373
ZINC ZINC000021297308